The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.
 
Nicholas D. James
Honoraria - Astellas Pharma; Bayer; Janssen; Oncogenex; Pierre Fabre; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Ferring; Janssen Oncology; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; Sanofi
 
Sarah Pirrie
No Relationships to Disclose
 
Wenyu Liu
No Relationships to Disclose
 
Daniel Ford
Honoraria - Astellas Pharma; Ipsen; Janssen
Consulting or Advisory Role - GenesisCare
Travel, Accommodations, Expenses - GenesisCare
 
Anjali Zarkar
Speakers' Bureau - EUSA pharma; Janssen Oncology; Pfizer; Sanofi
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Elizabeth Southgate
No Relationships to Disclose
 
Amisha Desai
No Relationships to Disclose
 
Syed A. Hussain
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Pfizer; Pierre Fabre; Roche; Sotio
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Pierre Fabre
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche